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Abstract. We have recently described the purification 
and characterization  of an  insulin-degrading  enzyme 
(IDE) from Drosophila melanogaster that can cleave 
porcine  insulin,  is highly  conserved through  evolution 
and  is developmentally  regulated.  We now report that 
the IDE is,  in fact,  an insulin  EGF-binding  protein 
(dpl00)  that we had  isolated previously from Drosoph- 
ila using an antihuman  EGF receptor antiserum.  This 
conclusion is based upon the following evidence.  (a) 
dpl00,  identified by its ability to cross-link  to labeled 
insulin,  EGF,  and transforming  growth factor-alpha 
(TGF-alpha),  and to be immunoprecipitated  by anti- 
EGF receptor antisera,  copurifies with the IDE activ- 
ity. Thus,  the purified IDE can be affinity labeled with 
either  L2q-insulin,  ~25I-EGF, or ~2q-TGF-alpha,  and this 
labeling is specifically inhibited  with unlabeled  insu- 
lin,  EGE  and the insulin  B chain.  (b) The antiserum 
to the human  EGF receptor,  which recognizes dpl00, 
is able to specifically immunoprecipitate  the insulin- 
degrading  activity.  (c) The purified IDE preparation 
contains  a  single protein of 110 kD which is recog- 
nized by both the anti-EGF  receptor antiserum  and 
anti-Drosophila IDE antiserum.  (d) Polyclonal antise- 
rum to the purified IDE,  which specifically recognized 
only the  ll0-kD band in Drosophila Kc cells,  im- 
munoprecipitates  dpl00 cross-linked  to  t2q-TGF-alpha 
and dpl00 cross-linked  to  ~2sI-insulin from the purified 
IDE preparation.  (e) EGF,  which competes with insu- 
lin for binding to dpl00,  also inhibits the degradation 
of insulin  by the purified IDE.  These  results raise the 
possibility that a  functional  interaction  between the in- 
sulin and EGF growth factor families can occur which 
is mediated by the insulin-degrading  enzyme. 
I 
N vertebrates, growth factors that are members of the in- 
sulin  and EGF families are integrally  involved in the 
stimulation of mitogenesis and control of cellular me- 
tabolism. Further understanding of their biochemical inter- 
actions could benefit from identification and investigation of 
proteins that bind these factors in genetically characterized 
lower organisms. 
One system that appears to be highly conserved between 
mammals  and Drosophila is that of insulin and its related 
proteins. An insulinlike activity in Drosophila has been de- 
scribed (10) and Drosophila homologues of the human insu- 
lin receptor have recently been identified (3,  12-14). In ver- 
tebrates, insulin-induced effects are initiated upon binding of 
insulin to a specific cell surface receptor. However, the actual 
mechanism by which insulin is degraded within the cell is 
not entirely clear. While evidence for lysosomal degradation 
of insulin exists (7-9),  a nonlysosomal insulin-specific de- 
grading  enzyme has been identified in mammals  that may 
also play a critical role in vivo (2, 18, 19). One approach to 
resolving which degradative pathway is important is to de- 
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termine whether these enzymes are present in evolutionar- 
ily distant organisms  that use insulin-related  hormones.  In 
fact, we have recently purified and characterized an insulin- 
degrading enzyme (IDE) ~ from the cytoplasm of Drosoph- 
ila (5), demonstrating that the nonlysosomal insulin degra- 
dation pathway is conserved. We have also demonstrated that 
the IDE is regulated during Drosophila development (20). 
The fact that such a system is so well conserved during evolu- 
tion suggests an important role for the IDE. 
A second system that has a counterpart in Drosophila is 
the gene for c-erb, which codes for the EGF receptor in ver- 
tebrates (16). To identify proteins related to the EGF receptor 
in Drosophila, we used polyclonal antisera that recognizes 
EGF receptors from a variety of species (1). This antisera 
reacts with the cytoplasmic domain of the EGF receptor con- 
taining the tyrosine kinase region. In the course of this inves- 
tigation, we identified not only a protein that corresponds to 
the Drosophila EGF receptor but, in addition, a growth fac- 
tor binding  protein  for both  insulin  and  EGF (21).  Based 
upon the recognition by anti-EGF  receptor antiserum  and 
l. Abbreviations  used in this paper:  IDE, insulin-degrading enzyme; TGF- 
alpha, transforming growth factor-alpha. 
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this latter protein (designated dpl00) might be a novel recep- 
tor distinct from the Drosophila homologues of the EGF and 
insulin receptors. To explore this possibility further, we char- 
acterized the binding spectrum, glycosylation state,  and cel- 
lular distribution of dpl00 (6).  The results  indicated that 
dpl00 is not a receptor, but a discrete binding protein for in- 
sulin and EGF-related factors. 
We now report that dpl00 is, in fact, the IDE that we had 
purified from Drosophila Kc cells.  Since EGF acts as an 
inhibitor of insulin degradation in this system, but is not de- 
graded at physiological concentrations,  it is  possible that 
EGF-like factors in Drosophila  can influence the degradation 
and ultimate action of the  insulin homologues in this  or- 
ganism. 
Materials and Methods 
Materials and Cells 
The Drosophila Kc cells, obtained from the Massachusetts Institute of Tech- 
nology Cell  Culture  Center,  Cambridge, MA,  were grown at  25°C  in 
D22 medium supplemented with yeast hydrolysate. Insulin and EGF were 
purchased from Biomedical Technologies,  Inc., Stoneham, MA. The mono- 
iodinated  J25I-insulin and  J2SI-EGF used for degradation assays  were pur- 
chased from New England Nuclear, Boston, MA. The recombinant trans- 
forming growth factor-alpha (TGF-alpha) was a girl from Dr. Rik Derynck, 
Genentech, San Francisco, CA and the synthetic TGF-alpha was a gift from 
Dr. James Tam, Rockefeller University, NY. Enzymobeads were from Bio- 
Rod Laboratories, Rockville Centre, NY.  Insulin, EGE and recombinant 
TGF-alpha, used for affinity labeling experiments, were iodinated using en- 
zymobeads as previously described (21) (final sp act ,~100/xCi/tzg).  The an- 
tihuman EGF receptor antiserum, which was generated against gel-purified 
EGF receptor, was described previously (1). 
TCA Precipitation Degradation  Assay 
Aliquots of Drosophila extracts, partially purified or purified IDE, were 
diluted into a buffer containing 50 nM insulin, 0.5 mg/ml BSA,  100 mM 
phosphate pH 7.2, and 25,000 cpm of monoiodinated insulin (sp act 80-120 
~C/ttg). The samples were incubated for 15 rain at 37°C and the incubation 
was stopped by the addition of cold 25 % TCA. The relative amount of re- 
leased radioactivity in the soluble fraction was determined as previously de- 
scribed (5). For 12SI-EGF-degradation  assays, unlabeled insulin was omit- 
ted. The extent of specific degradation was evaluated  by adding an excess 
of unlabeled insulin to parallel samples. All concentrations were chosen so 
that the extent of insulin degradation was linear with time and protein. Com- 
petition assays in the presence of EGF and their analysis were carried out 
as  described  (5).  HPLC  analysis  indicated  that  the  Drosophila IDE 
degraded insulin at  a  limited number of cleavage sites similar to those 
identified for the mammalian IDE (ha). 
Purification  of  the Drosophila Insulin-degrading  Enzyme 
The IDE was purified by successive chromatography on DEAE cellulose, 
Sephadex G-200,  hydroxylapatite,  butyl  agarose,  and  chromatofocusing 
columns as described (5). This IDE preparation contained a single protein 
band with molecular mass of 110,000 kD when analyzed by SDS-PAGE. For 
immunoprecipitation of enzyme activity by the anti-EGF receptor antibody 
and preparation of the polyclonal anti-Drosophila IDE antiserum, the gel 
filtration and chromatofocusing steps were omitted from the enzyme pu- 
rification. This latter preparation was used previously to characterize the 
properties of the Drosophila IDE (5). 
Preparation of the Polyclonal Anti-Drosophila 
IDE Antiserum 
Partially purified Drosophila IDE (80-120 #g) was loaded to a preparative 
6.5 % polyacrylamide gel under denaturing conditions as previously de- 
scribed (6). Proteins were visualized by staining with Coomassie Blue. The 
ll0,000-kD  protein band was excised, ground,  and injected directly in- 
traperitoneally into New Zealand rabbits at days 1, 21, 35, 51, and 122. The 
purity of the gel-purified ll0,000-kD protein was confirmed by NH2-ter- 
minal sequence analysis (5). Serum samples were obtained at day 1 before 
the first immunization (control serum), and at days 28, 43, 56, and 128. An- 
tibodies specifically reactive with the Drosophila IDE were detected after 
the second immunization. 
lmmunoblotting Analysis 
Protein samples were separated by PAGE, using 6.5% polyacrylamide gels 
under reducing conditions (6). The samples were then electrophoretically 
transferred from the gel to a nitrocellulose paper and the paper was probed 
with rabbit polyclonal antibodies as described and visualized using a Vecta- 
stain ABC Kit (Vector Laboratories, Inc.) (21). 
lmmunoprecipitation and Affinity Labeling 
Immunoprecipitation was performed with anti-EGF receptor antiserum or 
anti-Drosophila IDE antiserum in 50 mM Hepes buffer pH 7.5 overnight 
at 4°C followed by addition of protein A-Sepharose and affinity labeled un- 
der saturating conditions with 12Sl-insulin or 125I-TGF-alpha (10 rig) as pre- 
viously described (6, 21). For immunoprecipitation with the anti-Drosoph- 
ila IDE antiserum, protein samples were incubated in the presence of SDS 
and at different tempratures before incubation with antiserum. 
Binding to the EGF Receptor 
~2SI-EGF was incubated with the IDE as described above and samples re- 
moved at various times. Reactions were stopped by adding excess insulin 
or by two cycles of freeze thawing. Samples were then assayed for binding 
to the EGF receptor as described (4). 
Two-dimensional Polyacrylamide  Gel Electrophoresis 
High resolution two-dimensional electrophoresis of protein was performed 
as described (11). Electrophoresis on a tube gel in an ampholine gradient 
ranging from pH 3.5-10 was followed by SDS-PAGE on a 7.5% acrylamide 
slab gel. Protein markers were used to determine the pl of the resulting 
spots. 
Results 
We have previously isolated a protein (dpl00) from Drosoph- 
ila Kc cells with the unusual property that it could be affinity 
labeled  with either  mammalian  ~2sI-insulin or  ~25I-EGF at 
physiological concentrations, and in both cases the affinity 
labeling was inhibited by the addition of an excess of unla- 
beled insulin or EGF (21). This protein had a molecular mass 
of ,x,100-110 kD, and could be immunoprecipitated with an 
antiserum against the human EGF receptor. The protein was 
also  shown  to bind  related  factors,  such  as  transforming 
growth factor-alpha and insulinlike growth factor-II, with a 
relatively high affinity (Kd ,x, 10-9 M) (6). These properties 
were used as criteria to identify dpl00 in studies designed to 
elucidate its function. 
To determine the functional role of dpl00, it was necessary 
to purify the protein. In the course of this investigation, it 
became apparent that dpl00 copurified with an insulin-de- 
grading activity ODE) that we had identified and purified 
from Drosophila Kc cells (5). The coidentity of these two 
proteins was illustrated by the fact that the purified IDE could 
be directly affinity labeled with  either  J25I-insulin or  ~5I- 
TGF-alpha and, in both cases, the labeling was inhibited by 
the addition of an excess of either insulin or EGF (Fig.  1). 
If the two proteins, the IDE and dpl00, are in fact the same, 
they should share antigenic properties. Since the antiserum 
against the human EGF receptor can also immunoprecipitate 
dpl00, we determined whether this antiserum can selectively 
The Journal  of Cell Biology,  Volume 108, 1989  178 Figure 1. Autoradiograph depicting affinity labeling of ~251-insulin 
or ~25I-TGF-alpha  to purified IDE.  Purified Drosophila IDE (0.6 
#g) was affinity labeled with ~25I-insulin (lanes 1-4) or J25I-TGF- 
alpha (lanes 5-8) in the absence (lanes 1, 5) or presence of unla- 
beled insulin (10  -5 M, lanes 2, 6), insulin B chain (10  -4 M, lanes 
3,  7),  or EGF (2  ×  10  -5 M,  lanes 4,  8),  and analyzed as de- 
scribed in Materials and Methods.  Labeled  ~25I-insulin and  ~25I- 
TGF-alpha in the absence of IDE are shown in lanes 9 and 10, 
respectively. The lower bands are  nonspecifically labeled BSA 
which was included in the incubation mixture. 
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Figure 2.  Immunoprecipitation of insulin-degrading activity with 
an antihuman EGF receptor antiserum.  Partially purified IDE (1 
#g) was incubated with preimmune (8 ~tl, o) or anti-EGF receptor 
antiserum (4 tzl, ,,;  8 ~1,  A) at 4°C  overnight. The supernatant 
fractions of  the samples were assayed for insulin-degrading activity 
after  removal of the  antibodies with protein  A as described  in 
Materials and Methods. 
remove the insulin-degrading activity from a  partially pu- 
rified enzyme preparation. As shown in Fig. 2, the anti-EGF 
receptor antiserum precipitated the insulin-degrading activ- 
ity while  preimmune  serum  had  no effect.  Under similar 
conditions, this antiserum does not immunoprecipitate the 
Drosophila  insulin receptor (6).  These results suggest that 
dpl00 may have insulin-degrading activity. To explore this 
possibility  further,  we  also  prepared  specific  antiserum 
against the purified Drosophila  IDE. 
The 110-kD protein corresponding to the Drosophila  IDE 
was excised from polyacrylamide gels and used to prepare 
rabbit polyclonal antiserum against the IDE. Initial charac- 
terization of the resultant antiserum by immunoblotting indi- 
cated that the antibody specifically reacted with the IDE in 
crude cytoplasmic and membrane extracts of Kc ceils and 
with the purified !DE. However, no specific recognition of 
proteins in the membranes of A431 cells by the anti-IDE an- 
Table I. Similarities between dp  l O0 and the 
Drosophila IDE 
dpl00  IDE 
Relative  molecular mass (kD)  110  110 
Affinity labeling 
Insulin  +  + 
EGF  +  + 
TGF-aipha  +  + 
Immunocross reactivity 
Anti-EGF-receptor antiserum  +  + 
Anti-Drosophila-IDE 
antiserum  +  + 
Degradation 
Insulin  +  + 
EGF  -  - 
tiserum  was  detected (Fig.  3).  A431  cells,  which  contain 
large amounts of EGF receptor, were used as a  source of 
EGF receptor to prepare the antihuman EGF receptor antise- 
rum (2, 18, 19) that cross reacts with dpl00 (21). Therefore, 
we conclude that our antiserum is specific for the Drosophila 
IDE and does not cross react with the human or Drosophila 
EGF receptors. 
The purity of the ll0-kD IDE used for these experiments 
has previously been established by a number of criteria, in- 
cluding protein sequencing (5). When the purified enzyme 
preparation was immunoblotted with antiserum against the 
purified IDE and antiserum against the human EGF receptor, 
in  both cases  antigenic  reactivity was  observed (data  not 
shown), confirming the previous observations. The fact that 
both antisera were recognizing a single protein was further 
confirmed by immunoblots of IDE  after two-dimensional 
polyacrylamide gel electrophoresis. When resolved by mo- 
lecular mass and isoelectric focusing, only a single protein 
was noted by silver staining at  100-110 kD which reacted 
strongly with anti-Drosophila  IDE antiserum and  weakly 
with the antihuman EGF receptor antiserum (Fig. 4). In both 
cases, no other protein visibly reacted with the antiserum. 
These results further establish the antigenic cross-reactivity 
of the Drosophila  IDE and dpl00. 
This cross-reactivity was finally illustrated by direct im- 
munoprecipitation studies.  Above, we have shown that the 
antibody that immunoprecipitates dpl00 can also remove the 
insulin-degrading  activity.  Similarly,  we can  now demon- 
strate that antiserum against the Drosophila IDE is able to 
specifically immunoprecipitate purified IDE affinity labeled 
with TGF-alpha or insulin (Fig. 5). Nonspecifically labeled 
proteins, such as BSA in the labeled insulin and TGF-alpha 
preparations (Figs.  1 and  6),  were not recognized by the 
anti-IDE antiserum. Unfortunately, the anti-IDE antiserum 
does not efficiently precipitate the native enzyme; therefore, 
the addition of a denaturing detergent is required, enabling 
one to monitor precipitation of the affinity-labeled protein 
but not the enzymatic activity. In summary, the fact that the 
purified IDE has the distinctive characteristics of dpl00 and 
Garcia  et al.  Insulin EGF Binding Protein  179 Figure 3. Immunoblot illustrating  specificity  of antiserum against the Drosophila IDE. Samples  (1-30 #g) from purified Drosophila IDE 
(lanes 3, 7), Drosophila Kc cell membranes,  (lanes 4, 8), and Kc cytoplasm (lanes 5, 9), as well as human A431 cell membranes (lanes 
2, 6), were resolved by SDS-PAGE, transferred  to nitrocellulose,  and blotted with either preimmune serum (lanes 2-5) or anti-IDE antise- 
rum (lanes  6--9) as described in Materials  and Methods.  Molecular mass markers (x  10  -3) are shown in lane 1. 
shares physical and antigenic properties argues that the two 
proteins are,  in fact,  the same. 
Given that the Drosophila IDE can bind to EGF, the ques- 
tion arises regarding the physiological reason for this interac- 
tion.  Therefore,  we determined  whether  EGF  might be  a 
substrate  for the enzymatic-degrading activity.  Two assays 
were used to assess the state of the growth factors: (a) the 
TCA  precipitation  assay  which  monitors  release  of small 
Figure 4. Immunoblot illustrating comigration of the Drosophila IDE and dpl00 after two-dimensional  polyacrylamide gel electrophoresis. 
Partially purified IDE (5/tg) was resolved by isoelectric focusing and SDS polyacrylamide gel electrophoresis  as described.  (A) Immunoblot 
of IDE reacted  with anti-Drosophila IDE antiserum; (B) immunoblot of IDE reacted  with antihuman EGF receptor antiserum; (C) gel 
stained with Pierce Gelcode color silver stain. Molecular mass markers (x  l0  -3) are indicated.  The position of the IDE is indicated with 
an arrow. 
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Figure 5. Immunoprecipitation of the IDE affinity labeled with in- 
sulin and TGF-alpha. Lanes 1-4, 25 t*l of t25I-insulin-labeled IDE  ,~  20 
were untreated (lanes 1, 3) or heated for 5 rain at 100°C in 0.5%  ta 
,It  SDS. Samples were then diluted to 0.1% SDS in PBS and immuno-  ¢ 
precipitated with 5 #1 preimmune (lanes 1, 2) or 5 #1 anti-IDE an-  ua 
tiserum  (lanes 3, 4).  Lanes 5,  6, 20/~1 of ~2SI-TGF-alpha-labeled  ,~  10 
IDE were heated at 100°C for 5 min in 0.5%  SDS (lane 5) or 1% 
SDS (lane 03, diluted to 0.1% SDS with PBS, and then immunopre- 
cipitated with 5/~1 preimmune (lane 5) or 5 #1 anti-IDE antiserum  0  o 
(lane 6). 
fragments into the non-TCA-precipitable fraction and (b) a 
receptor-binding assay which measures the remaining frac- 
tion of intact growth factor by the ability to bind to the EGF 
receptor.  As demonstrated with insulin,  the latter assay is 
more sensitive to limited cleavage (15). In contrast to the case 
with insulin, the IDE was unable to degrade EGF (Fig. 6). 
Since EGF does not appear to be a  substrate for the en- 
zyme, we determined whether it can act as an inhibitor of 
insulin  degradation.  EGF  and  insulin  were  preincubated 
with IDE for 30 min at 4°C before addition of labeled insu- 
lin. As shown in Fig. 7, both EGF and insulin significantly 
inhibited degradation of insulin  at a  concentration of 5  x 
10  -6 M.  Further  kinetic analysis of the inhibition by EGF 
suggests that EGF might act as a competitive inhibitor (data 
not shown) indicative of a  single site for both the substrate 
and  inhibitor  (17).  These results  clearly demonstrate that 
EGF is able to directly interact with a highly conserved Dro- 
sophila enzyme and block is ability to degrade mammalian 
insulin. 
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The results we have presented here show that the insulin EGF 
binding protein (dpl00) previously characterized by our lab- 
oratory is an insulin-degrading enzyme. This identity was es- 
tablished  by a  number of criteria:  First,  the  insulin  EGF 
binding  protein  copurified  with  the  insulin-degrading  en- 
zyme from Kc cells, and the purified enzyme exhibited bind- 
ing properties characteristic of dpl00. Thus, the purified IDE 
had the same molecular weight and isoelectric point, could 
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Figure 6. Lack of EGF degradation by the Drosophila IDE. (Top) 
EGF bnding assay. Samples containing purified IDE (0.4 #g) were 
incubated with t25I-EGF (10  -9 M) for the indicated time periods, 
and then assayed for binding to the  EGF receptor  as described. 
Nonspecific binding (209 cpm), determined by adding 1.5  ×  10  -7 
M unlabeled EGF, was subtracted from the final values. (Bottom) 
TCA precipitation assay. Samples containing purified IDE (0.4 tzg) 
were incubated with either  J25I-insulin  (10 -9  M,  O,  I) or ~25I-EGF 
(10  -9 M, ~, m) for the indicated time periods in either the absence 
(o, ~) or presence (e, u) of 5  x  10  -6 M unlabeled insulin. 
be affinity labeled with both EGF and TGF-alpha as well as 
insulin, and the latter could be inhibited with both EGF and 
insulin-related  factors.  Second,  the antigenic properties of 
the two proteins were indistinguishable.  The enzymatic ac- 
tivity could be selectively removed by immunoprecipitation 
with the anti-EGF receptor antibody that recognized dpl00. 
Conversely, antisera against the purified IDE could immuno- 
precipitate  the  100-kD  protein  affinity labeled  with  TGF- 
alpha or insulin. Two-dimensional polyacrylamide gel elec- 
trophoresis confirmed that the purified enzyme corresponded 
to a single band that could be recognized by either antiserum. 
Finally, the kinetic properties of the IDE reflected the ability 
of the enzyme to bind EGF-related factors. Thus, although 
the Drosophila enzyme did not degrade EGF, EGF was able 
to inhibit degradation of insulin. In sum, on the basis of phys- 
ical, antigenic, and functional criteria, the Drosophila IDE 
is also an EGF binding protein. 
One surprising feature of this finding is that, although the 
IDE is able to recognize EGF, there is, to date, no homologue 
of EGF  that has  been identified  in Drosophila.  However, 
there is evidence to suggest that related factors may exist. For 
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Figure 7. Inhibition of Drosophila  IDE insulin degradation  by insu- 
lin and EGF. Samples containing purified IDE (0.2 #g) were as- 
sayed for ~25I-insulin  degradation by the TCA precipitation assay in 
the absence (0) or presence of 5  x  10  -6 M unlabeled insulin (o) 
or EGF (m) for the indicated time periods. 
example,  the gene coding for the Notch mutation has been 
sequenced and shown to code for cysteine-rich protein with 
similar spacing of cysteine as in EGF (22).  A  similar type 
of gene has also been located in nematodes (denoted lin). 
The fact that the IDE is able to bind mammalian EGF may 
provide further evidence for EGF-like factors in Drosophila. 
Having established this identity, it is of interest to deter- 
mine the physiological impact of this relationship between 
the two growth factor families.  Although receptors are not 
entirely specific,  there is no documented case of an insulin 
receptor responding to EGF, or vice versa. Yet the levels of 
ligands, as determined in part by the degradation pathway, 
might influence the extent of receptor-mediated  signaling. 
Thus, the IDE provides one mechanism whereby EGF can 
influence  the extent of insulin degradation.  The  fact  that 
growth-related factors can regulate the action of the IDE may 
provide an alternative regulatory mechanism and is consis- 
tent with our recent observation that the IDE is developmen- 
tally regulated, being present only at low levels in the rapidly 
growing embryonal stage  (20).  In the Drosophila  system, 
there is no evidence that the IDE can directly degrade mam- 
malian EGE  However, since this is a heterologous system, 
it is possible that there is an EGF homologue in Drosophila 
that could be a substrate for the enzyme. 
One of the most striking features of this work is the high 
conservation of the IDE between mammals and Drosophila. 
Although we detected the EGF binding to the Drosophila 
IDE,  we have now demonstrated that EGF,  while not de- 
graded at physiological concentrations, can inhibit insulin 
degradation by the rat liver IDE in a similar manner (Garcia, 
J.  V.,  and M.  R.  Rosner, manuscript submitted for publi- 
cation).  Thus,  the existence  of a protein that can mediate 
binding of insulin and EGF at possibly a single site in both 
mammals and Drosophila suggests that this property is an 
important one in the function of the enzyme and the role it 
plays in maintaining growth factor levels. 
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